Breadcrumb

[A19-12] Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2019-02-04 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Executive summary of dossier assessment  [PDF, 105 kB] (German version) Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A19-54] Nivolumab (renal cell carcinoma) - Addendum to Commissions A19-11 and A19-12
Status: Commission completed

[A18-44] Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A18-12] Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A13-44] Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed

[A12-07] Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-05-15 Executive summary of dossier assessment (German version) 105 kBPDFdownload file
2019-05-15 Dossier assessment (German version) 959 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Federal Joint Committee (G-BA)

2019-08-15 A G-BA decision was published.

G-BA documents on this decision

Press releases

2019-05-15 Nivolumab with ipilimumab: drug combination has added benefit in advanced renal cell carcinoma



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close